XTL Biopharmaceuticals Faces Nasdaq Delisting Over 'Public Shell' Status

Key Facts

1XTL Biopharmaceuticals received a notice from Nasdaq stating it is no longer warranted for continued listing.

2Nasdaq Staff believes the company is a 'public shell' pursuant to Nasdaq Listing Rule 5101.

3The company intends to request a hearing to appeal, which will stay the suspension and delisting pending a decision.

XTL Biopharmaceuticals Ltd. (XTLB) has received a formal notice from Nasdaq indicating that its shares are no longer suitable for continued listing. The Nasdaq Listing Qualifications Department based its decision on Rule 5101, categorizing the company as a "public shell" lacking sufficient core operations. This determination typically signals a lack of active business substance, which can severely impact investor confidence and stock liquidity. In response, XTL Biopharmaceuticals announced its intention to request a hearing to appeal the staff's determination. The request for a hearing will effectively stay the suspension and delisting process until a final decision is reached by the Nasdaq Hearings Panel. Despite the temporary stay, the company's future on the exchange remains uncertain as it attempts to prove its compliance with listing standards.